Industry

FDA Approves Extension of Dosing Intervals for Regeneron's Eylea HD

Vision Monday7h ago1 min read

TARRYTOWN, N.Y.—Regeneron Pharmaceuticals, Inc., a leading biotechnology company, (NASDAQ: REGN) announced that the U.S. Food and Drug Administration (FDA) has approved the extension of dosing intervals for Eylea HD (aflibercept) up to every 20 weeks for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) following one year of successful response based on visual and anatomic outcomes. Eylea was originally approved by the FDA in August 2023. As part of the approval, the FDA has updated the Eylea HD label to include 96-week (2-year) data from the pivotal PULSAR trial in wAMD and the pivotal PHOTON trial in DME, demonstrating sustained efficacy and safety through two years with extended dosing intervals, the announcement said.

Read full article on Vision Monday

AI Summary

Quick Take

The FDA has approved a label expansion for Eylea HD (aflibercept 8mg), allowing for dosing intervals of up to every 20 weeks in patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). This extension is applicable for patients who demonstrate a successful visual and anatomic response after one year of treatment.

Why It Matters

Reducing treatment burden is a critical priority in retina care, as frequent injections often lead to patient fatigue and suboptimal real-world outcomes. By extending the maximum dosing interval to 20 weeks—nearly five months—clinicians can potentially maintain vision with as few as three injections per year for stable patients. This approval reinforces the competitive position of high-dose aflibercept in a market increasingly focused on durability and long-acting therapies.

Key Findings

The FDA approval extends the maximum dosing interval for Eylea HD from 16 weeks to 20 weeks for both wAMD and DME.
Approval is based on 96-week (two-year) data from the pivotal PULSAR and PHOTON clinical trials.
Extended dosing is indicated specifically for patients who have shown a successful response during their first year of therapy.
The updated label confirms that sustained efficacy and safety are maintained through two years of treatment with these longer intervals.

Study Snapshot

Design

Pivotal Phase 3 clinical trials (PULSAR and PHOTON)

Population

Patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME)

Practice Implications

Retina specialists can now further individualize 'treat-and-extend' protocols, offering a 20-week interval to stable patients who meet visual and anatomic criteria. This flexibility may improve long-term compliance and clinic efficiency by reducing the total number of annual office visits and injections required for a significant subset of the patient population.

Who's Affected

Retina SpecialistsOphthalmologistsPractice Owners

What's Next

Clinicians will likely begin identifying candidates for the 20-week extension among patients currently stable on 12- or 16-week Eylea HD regimens. Future real-world data will clarify what percentage of the broader patient population can successfully maintain vision at this maximum interval.

Evidence StrengthStrong

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.